Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 296

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Systematic review with meta‐analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials

Open access
Cholapranee, A., Hazlewood, G. S, Kaplan, G. G., Peyrin‐Biroulet, L., Ananthakrishnan, A. N.·2017·Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background: Mucosal healing is an important therapeutic endpoint in the management of Crohn's disease ( CD ) and ulcerative colitis ( UC ). Limited data exist regarding the comparative efficacy of various therapies in achieving this outcome. Aim: To perform a systematic review and meta‐analysis of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis. Methods: We performed a systematic review and meta‐analysis of randomised controlled trials ( RCT ) examining mucosal healing as an endpoint of immunosuppressives, anti‐tumour necrosis factor α (anti‐ TNF ) or anti‐integrin monoclonal antibody therapy for moderate‐to‐severe CD or UC . Pooled effect sizes for induction and maintenance of mucosal healing were calculated and pairwise treatment comparisons evaluated using a Bayesian network meta‐analysis. Results: A total of 12 RCT s were included in the meta‐analysis ( CD – 2 induction, 4 maintenance; UC – 8 induction, 5 maintenance). Duration of follow‐up was 6–12 weeks for induction and 32‐54 weeks for maintenance trials. In CD , anti‐ TNF s were more effective than placebo for maintaining mucosal healing [28% vs. 1%, Odds ratio ( OR ) 19.71, 95% confidence interval ( CI ) 3.51–110.84]. In UC , anti‐ TNF s and anti‐integrins were more effective than placebo for inducing (45% vs. 30%) and maintaining mucosal healing (33% vs. 18%). In network analysis, adalimumab therapy was inferior to infliximab [ OR 0.45, 95% credible interval (CrI) 0.25–0.82] and combination infliximab‐azathioprine ( OR 0.32, 95% CrI 0.12–0.84) for inducing mucosal healing in UC . There was no statistically significant pairwise difference between vedolizumab and anti‐ TNF agents in UC . Conclusions: Anti‐ TNF and anti‐integrin biological agents are effective in inducing mucosal healing in UC , with adalimumab being inferior to infliximab or combination therapy. Infliximab and adalimumab were similar in CD .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.14030

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 296

Metadata

Authors
Cholapranee, A., Hazlewood, G. S., Kaplan, G. G., Peyrin‐Biroulet, L., & Ananthakrishnan, A. N.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2017-03-22
Volume
45
Issue
10
Pages
1291-1302
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2598864494
Cited by
296
References
54
FWCI
4.46
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systematic review with meta‐analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. https://app.cochat.ai/papers/10.1111/apt.14030
The paper
Cholapranee, A., Hazlewood, G. S., Kaplan, G. G., Peyrin‐Biroulet, L., & Ananthakrishnan, A. N. (2017). Systematic review with meta‐analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.14030

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.